Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-aminocyclopentane-1,3-dicarboxylic acid
- Development stage
- Preclinical
- Lead developer
- University of South Florida
- Modality
- Small Molecules
- Administration
- Intrathecal
01
Overview
ACPD (1-aminocyclopentane-1,3-dicarboxylic acid) is a small molecule that serves as a broad-spectrum agonist of metabotropic glutamate receptors (mGluRs). While primarily recognized in neuroscience as a pharmacological tool for studying excitatory neurotransmission, research from the University of South Florida (Acevedo-Duncan lab) has identified ACPD as an inhibitor of atypical protein kinase C (aPKC) isoforms, specifically PKC-zeta (ζ) and PKC-iota (ι). In preclinical studies, ACPD has demonstrated the ability to decrease cell proliferation and potentially inhibit cell motility in metastasized melanoma cell lines, such as SK-MEL-2, without affecting normal melanocytes. Its role as an aPKC inhibitor suggests potential applications in oncology, particularly for cancers driven by atypical PKC signaling, such as malignant melanoma.
- Other names
- 1-amino-1,3-dicarboxycyclopentane(±)-trans-1-aminocyclopentane-1,3-dicarboxylic acid
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)GRM1 (Metabotropic glutamate receptor 1)GRM2 (mGluR2)GRM3 (mGluR3)GRM5 (Metabotropic glutamate receptor 5)GRM4 (mGluR4)
Beyond the preview
Go deeper on 1-aminocyclopentane-1,3-dicarboxylic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1-aminocyclopentane-1,3-dicarboxylic acid.